

- **Name:** Woo Kyun Bae
 - **Current Position & Affiliation:** Professor, Hematology-Oncology, Chonnam National University Hwasun Hospital
 - **Country:** Republic of Korea
-

• **Educational Background:**

- 1992 - 1998: M.D., Chonnam National University, College of Medicine, Korea
- 2008 - 2011: Ph.D., Chonnam National University, College of Medicine, Korea
- 2012 – 2014: Post-doctoral fellow, NIDDK, NIH, Bethesda, USA

• **Professional Experience:**

- 1999 - 2006: Intern/Resident, Internal Medicine, Chonnam National University Hospital, Korea
- 2006 - 2008: Fellow/Staff Clinician, Nephrology, Chonnam National University Hospital, Korea
- 2008 – present: Staff Clinician, Hematology-Oncology, Chonnam National University/Hwasun Hospital, South Korea

• **Professional Organizations:**

- Active/Past member of Korean Society of Nephrology (KSN)
- Active member of Korean Society of Medical Oncology (KSMO)
- Active member of Korean Cancer Study Group (KCSG)
- Active member of Korean Cancer Association (KCA)
- Active member of American Association for Cancer Research (AACR)

• **Main Scientific Publications:**

1. Yoo KH, Kim DH, Oh S, Park MS, Kim H, Ha HH, Cho SH, Chung IJ, Bae WK. Transcriptome analysis upon potassium usnate exposure reveals ATF3-induced apoptosis in human gastric and colon cancer cells. *Phytomedicine*, 91:153655, 2021
2. Lau-Corona D, Bae WK, Hennighausen L, Waxman DJ. Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. *PLOS Genet*, 16(5):e1008796, 2020
3. Uthaman S, Pillarisetti S, Mathew AP, Kim Y, Bae WK, Huh KM, Park IK. Long circulating photoactivable nanomicelles with tumor localized activation and ROS triggered self-accelerating drug release for enhanced locoregional chemo-photodynamic therapy. *Biomaterials*, 232:119702, 2020
4. Bae WK, Lee HJ, Park SH, Kim JH, Kim HJ, Maeng CH, Park I, Sohn BS, Kim JA, Lee KH, Lim DH, Chang H, Kim SM, Kim HY, Song H, Lim S, Byun JH, Jung HA. Comparative

15th Annual Meeting of the Korean Society of Medical Oncology & 2022 International Conference

- effectiveness of palliative chemotherapy versus neoadjuvant chemotherapy followed by radical cystectomy versus cystectomy followed by adjuvant chemotherapy versus cystectomy for regional node-positive bladder cancer: A retrospective analysis: KCSG GU 17-03. *Cancer Med*, 8(12):5431-5437, 2019
5. Choi W, Kim JG, Beom SH, Hwang JE, Shim HJ, Cho SH, Shin MH, Jung SH, Chung IJ, Song JY, Bae WK. Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial. *Cancer Res Treat*, 52(1):246-253, 2019
 6. Bae WK, Kwon J, Lee HW, Lee SC, Song EK, Shim H, Ryu KH, Song J, Seo S, Yang Y, Park JH, Lee KH, Han HS. Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study. *Support Care Cancer*, 26(11):3721-3728, 2018
 7. Ahn MJ, Lee K, Lee KH, Kim JW, Kim IY, Bae WK. Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report. *BMC Cancer*, 18(1):173, 2018
 8. Bae WK, Hong CS, Park MR, Sun EG, Lee JH, Kang K, Ryu KH, Shim HJ, Hwang JE, Cho SH, Chung IJ. Tap73 inhibits cell invasion and migration by directly activating KAI1 expression in colorectal carcinoma. *Cancer Lett*, 415:106-116, 2018
 9. Kim KR, Shim HJ, Hwang JE, Cho SH, Chung IJ, Park KS, Kang SR, Kwon SY, Chung WK, Bae WK. The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer. *Eur J Nucl Med Imaging*, 45(2):170-178, 2018
 10. Kang SH, Revuri V, Lee SJ, Cho S, Park IK, Cho KJ, Bae WK and Lee YK. Oral siRNA Delivery to Treat Colorectal Liver Metastases, *ACS Nano*, 24;11(10):10417-10429, 2017
 11. Bae WK, Yoo KH, Lee JS, Kim Y, Chung IJ, Park MH, Yoon JH, Furth PA, Hennighausen L. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. *Mol Carcinog*. 54(10):1172-80, 2015
 12. Bae WK, Kang K, Yu JH, Yoo KH, Factor VM, Kaji K, Matter M, Thorgeirsson S, Hennighausen L. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration. *FASEB J*. 29(5):1653-62, 2015